Answers are grounded in this paper and cite their sources.
Emphasizes controlling metabolic syndrome to lower cardiovascular disease risk in patients with hyperuricemia or gout, highlighting the need for long-term clinical trials.
Clinicians should be aware of the presence of metabolic syndrome in patients with hyperuricemia or gout in order to control its components (high blood pressure, obesity, etc.) and hence reduce the risk for cardiovascular disease. Long-term, randomized interventional clinical trials are needed to test the hypothesis that urate-lowering therapy can reduce cardiovascular risk in these patients.
No takes yet. Share an insight, caveat, or question.
Puig et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: